MARY STEDMAN: Open Payments
NPI 1457304644 · TAMPA, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,642 in 80 payments from 14 companies in 2025. Trend: 2023 $1,677 · 2024 $8,086 · 2025 $4,642
Food & beverage: $2,611Travel & lodging: $2,031
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 20 | $2,818 |
| Eisai Inc. | 16 | $565 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $282 |
| Alkermes, Inc. | 9 | $212 |
| Axsome Therapeutics, Inc. | 4 | $169 |
| Otsuka America Pharmaceutical, Inc. | 11 | $148 |
| Teva Pharmaceuticals USA, Inc. | 1 | $117 |
| E.R. Squibb & Sons, L.L.C. | 1 | $90 |
| ABBVIE INC. | 4 | $80 |
| Lundbeck LLC | 2 | $48 |
Products named: Leqembi, CAPLYTA, ARISTADA, REXULTI, Auvelity, AUSTEDO XR, COBENFY, VRAYLAR.
Industry payments across FL — which companies pay providers there.
